Granules India Extends Rally for Fifth Straight Session

As on 22 December 2025,

extended its upward momentum, gaining around 3% and marking its fifth consecutive winning session. The positive move followed regulatory developments at its subsidiary, Granules Life Sciences (GLS), Hyderabad. The US Food and Drug Administration has completed a Good Manufacturing Practices and Prior Approval Inspection at the facility, conducted between December 15 and 19. The inspection resulted in five observations, all related to procedural requirements. Importantly, none of the observations were linked to data integrity or product safety concerns. GLS is engaged in manufacturing PFI and finished dosage formulations. The continued price strength reflected steady market sentiment after the inspection outcome, supporting buying interest in recent sessions. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. AI may have been used for grammatical and sentence-structure refinement. Please consult a SEBI-registered advisor before making any investment decisions.